Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles

Journal of Lipid Research

Volumn 45, Issue 3, 2004, Pages 592-601

  Frederiksen, Klaus Stensgaard ^a   Wulff, Erik Max ^a   Sauerberg, Per ^a   Mogensen, John Patrick ^a   Jeppesen, Lone ^a   Fleckner, Jan ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Dyslipidemia; Peroxisome proliferator activated receptor in vivo activation; Pharmacodynamics; Transcriptional profiling

Indexed keywords

COMPLEMENTARY DNA; FENOFIBRATE; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; GENE CONTROL; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; LIPID METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION;

EID: 1542723720     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300239-JLR200     Document Type: Article

References (37)

1. Issemann, I., and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347: 645-650.
2. Dreyer, C., G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli. 1992. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68: 879-887.
3. Tugwood, J. D., I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green. 1992. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11: 433-439.
4. Gulick, T., S. Cresci, T. Caira, D. D. Moore, and D. P. Kelly. 1994. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. Sci. USA. 91: 11012-11016.
5. Muerhoff, A. S., K. J. Griffin, and E. F. Johnson. 1992. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J. Biol. Chem. 267: 19051-19053.
6. Martin, G., K. Schoonjans, A. M. Lefebvre, B. Staels, and J. Auwerx. 1997. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 272: 28210-28217.
7. Schoonjans, K., J. Peinado-Onsurbe, A. M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPAR alpha and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348.
8. Vu, D. N., K. Schoonjans, B. Laine, J. C. Fruchart, J. Auwerx, and B. Staels. 1994. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269: 31012-31018.
9. Vu, D. N., K. Schoonjans, V. Kosykh, J. Dallongeville, J. C. Fruchart, B. Staels, and J. Auwerx. 1995. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96: 741-750.
10. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. B. Brewer, J. C. Fruchart, V. Clavey, and B. Staels. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
11. Staels, B., D. N. Vu, V. A. Kosykh, R. Saladin, J. C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95: 705-712.
12. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 57: 65-74.
13. Sadowski, I., B. Bell, P. Broad, and M. Hollis. 1992. GAL4 fusion vectors for expression in yeast or mammalian cells. Gene. 118: 137-141.
14. Webster, T. D., and R. C. Dickson. 1988. Nucleotide sequence of the galactose gene cluster of Kluyveromyces lactis. Nucleic Acids Res. 16: 8192-8194.
15. Cantello, B. C. C., M. A. Cawthorne, D. Haigh, R. M. Hindley, S. A. Smith, and P. L. Thurlby. 1994. The synthesis of brl-49653-a novel and potent antihyperglycemic agent. Bioorg. Med. 4: 1181-1184.
16. Sauerberg, P., I. Pettersson, L. Jeppesen, P. S. Bury, J. P. Mogensen, K. Wassermann, C. L. Brand, J. Sturis, H. F. Woldike, J. Fleckner, A. S. T. Andersen, S. B. Mortensen, L. A. Svensson, H. B. Rasmussen, S. V. Lehmann, Z. Polivka, K. Sindelar, V. Panajotova, L. Ynddal, and E. M. Wulff. 2002. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPAR alpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45: 789-804.
17. Mogensen, J. P., P. Sauerberg, P. S. Bury, L. Jeppesen, and I. Pettersson. 2001. Propionic acid derivatives and their use in the treatment of diabetes and obesity. US patent WO 01/55085 A1.
18. Mogensen, J. P., P. Sauerberg, P. S. Bury, L. Jeppesen, and I. Pettersson. 2001. Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity. US patent WO 01/55086 A1.
19. Albrektsen, T., K. S. Frederiksen, W. E. Holmes, E. Boel, K. Taylor, and J. Fleckner. 2002. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes. 51: 1042-1051.
20. Wold, S., M. Sjoström, and L. Eriksson. 2001. PLS-regression: a basic tool of chemometrics. Chemometr. Intell. Lab. Syst. 58: 109-130.
21. Krause, B. R., R. Bousley, K. Kieft, D. Robertson, R. Stanfield, E. Urda, and R. S. Newton. 1994. Comparison of lifibrol to other lipid-regulating agents in experimental animals. Pharmacol. Res. 29:345-357.
22. Cignarella, A., M. Nastasi, E. Cavalli, and L. Puglisi. 1996. Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidemia: a comparison with ciprofibrate. Thromb. Res. 84: 311-322.
23. Naderali, E. K., L. C. Pickavance, J. P. H. Wilding, P. J. Doyle, and G. Williams. 2001. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. Eur. J. Pharmacol. 416: 133-139.
24. Krause, B. R., and H. M. G. Princen. 1998. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis. 140: 15-24.
25. Haubenwallner, S., A. D. Essenburg, B. C. Barnett, M. E. Pape, R. B. DeMattos, B. R. Krause, L. L. Minton, B. J. Auerbach, R. S. Newton, T. Leff, and C. L. Bisgaier. 1995. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid Res. 36: 2541-2551.
26. Krause, B. R., and R. S. Newton. 1986. Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis. 59: 95-98.
27. Petit, D., M. T. Bonnefis, C. Rey, and R. Infante. 1988. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis. 74: 215-225.
28. Bardot, O., T. C. Aldridge, N. Latruffe, and S. Green. 1993. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem. Biophys. Res. Commun. 192: 37-45.
29. Bell, D. R., N. J. Plant, C. G. Rider, L. Na, S. Brown, I. Ateitalla, S. K. Acharya, M. H. Davies, E. Elias, and N. A. Jenkins. 1993. Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem. J. 294: 173-180.
30. Gould-Rothberg, B. E., S. S. Sundseth, V. A. DiPippo, P. J. Brown, D. A. Winegar, W. K. Gottshalk, S. G. Shenoy, and J. M. Rothberg. 2001. The characterization of PPAR-alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. Funct. Integr. Genomics. 1: 294-304.
31. Ouali, F., F. Djouadi, C. Merlet-Benichou, and J. Bastin. 1998. Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney. Am. J. Physiol. 44: F777-F784.
32. Schoonjans, K., M. Watanabe, H. Suzuki, A. Mahfoudi, G. Krey, W. Wahli, P. Grimaldi, B. Staels, T. Yamamoto, and J. Auwerx. 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270: 19269-19276.
33. Elholm, M., G. Bjerking, J. Knudsen, K. Kristiansen, and S. Mandrup. 1996. Regulatory elements in the promoter region of the rat gene encoding the acyl-CoA-binding protein. Gene. 173: 233-238.
34. Rodriguez, J. C., G. Gil-Gomez, F. G. Hegardt, and D. Haro. 1994. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269: 18767-18772.
35. Castelein, H., T. Gulick, P. E. Declercq, G. P. Mannaerts, D. D. Moore, and M. I. Baes. 1994. The peroxisome proliferator activated receptor regulates malic enzyme gene-expression. J. Biol. Chem. 269: 26754-26758.
36. Kim, H., J. Kim, S. Kim, J. Y. Cha, K. S. Kim, and Y. Ahn. 2000. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes. 49: 1517-1524.
37. Maxwell, K. N., R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow. 2003. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119.